Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
124
resultados
Última actualización
05/04/2026 [08:01:00]
Resumen de: US20260092052A1
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof.wherein each symbol is as described in the specification, or a salt thereof.
Resumen de: US20260092039A1
Compounds (I) are provided, where R1 and R2 are H or (C1-C3)-alkyl; X is a linear methylene chain of formula —CH2n— with n=0, 1 or 2, or a biradical from a branched saturated (C2-C4)-alkylene chain; and A is either a C-radical from a non-aromatic polycyclic 6- to 15-membered carbocyclic ring system, or a C-radical from a polycyclic 6- to 15-membered heterocyclic ring system having one or two O, S or N; wherein the C-radicals are unsubstituted or substituted. Compounds (I) are simultaneously inhibitors of soluble epoxide hydrolase and inhibitors of glutaminyl cyclase. Besides, they reduce the levels of pro-inflammatory cytokines in LPS stimulated BV2 cells, display low cytotoxicity, and have good BBB permeability. Thus, they are useful as multitarget compounds for the prevention or treatment of Alzheimer's disease.
Resumen de: US20260091047A1
Provided are therapeutic combinations, pharmaceutical compositions, and pharmaceutical kits comprising bioactive molecules from fungi, plants, and algae. In some embodiments, the fungi are from any psilocybin-producing fungi, such as from Psilocybe spp. fungi. In some embodiments, the plants are from either or both of the Cannabis and Dipteryx genera. In some embodiments, the algae may be marine algae, such as from the family Bangicacae, including the Pyropia and Porphyra genera. Methods of producing the disclosed combinations, compositions, and kits are also provided, such as using natural, biosynthetic, or synthetic means. Further provided are methods of using the disclosed combinations, compositions, and kits in treatment, and in particular for movement disorders, such as for Parkinson's disease, and the disclosed combinations are demonstrated to provide significant advantages in the treatment thereof.
Resumen de: US20260091028A1
Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine or pharmaceutically acceptable salt thereof.
Resumen de: US20260091009A1
Methods of treating Alzheimer's disease and other neurodegenerative and/or neurocognitive and/or neurodevelopmental diseases are described. The methods comprise the administration of compounds that modulate an activity of cell division control protein 42 (Cdc42), such as the interaction between Cdc42 and intersectin (ITSN). Exemplary modulator compounds include thioureas, disulfonamides of fused aromatic systems (e.g., benzofuran), and acyl hydrazones, among others. Some of the modulator compounds act as activators of Cdc42, while others act as inhibitors. In some cases, the modulator compound has dual functionality and the ability of the modulator compound to act as an inhibitor or activator depends on whether or not Cdc42 is already activated in a particular disease stage or biological environment by an upstream activating signal of Cdc42.
Resumen de: US20260091129A1
Provided are a nanocomposite for targeted degradation of a pathogenic protein, a preparation method therefor, and use thereof, which pertain to the technical field of nanobiological drugs. The nanocomposite for targeted degradation of the pathogenic protein is provided, which comprises a nanocarrier and a protein-targeting binding peptide grafted on the nanocarrier. The nanocarrier is a nanoassembly of maleimide-polyethylene glycol-polylactic acid and cationic lipids; on the other hand, the use of the nanocomposite in the preparation of drugs including an anti-tumor nanodrug and a Huntington's disease inhibiting drug is provided. The nanocomposite can simulate a key receptor protein in a selective autophagy pathway, so that the pathogenic protein to be degraded can be brought into an autophagosome to be degraded by means of an autophagy pathway, thereby effectively solving the problem that PROTACs cannot degrade large-molecular-weight protein aggregates and LYTACs cannot degrade cytoplasmic proteins.
Resumen de: US20260091109A1
A method for treatment of a human patient for Alzheimer's disease (AD) comprises sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to the patient. In preferred embodiments, the antibody is administered in increasing amounts over a period of time. In preferred embodiments, the susceptibility of the patient to amyloid related imaging abnormalities (ARIA) is thereby reduced.
Resumen de: AU2024352916A1
Provided are compounds of Formula (I) and related compositions and methods, including methods of therapy for treating neurological diseases and disorders, including multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), and methods for in vivo imaging of AMPA receptor, or surrogate thereof, in the brain.
Resumen de: AU2024344683A1
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of Parkinson's disease. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating Parkinson's disease.
Resumen de: US20260091025A1
The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.
Resumen de: WO2024263701A1
The present disclosure generally relates to novel chimeric antigen receptors ("CARs"), modified regulatory T cells ("Tregs") expressing such CARs and/or Tregs which are engineered to express neurodegenerative disease modifying molecules, optionally, which express molecules which prevent oxidative/inflammatory activity, or which promote neuronal growth/survival such as nerve growth factors or non-classical neurotrophic factors, compositions containing, and methods of use as therapeutics, in particular for treating and preventing neurodegenerative diseases and symptoms associated therewith. The present disclosure more specifically relates to novel chimeric antigen receptors ("CARs"), modified regulatory T cells ("Tregs") expressing such CARs and/or Tregs which are engineered to express a CAR which binds to TAR DNA-binding protein 43 (TDP-43), and the use thereof for treating subjects having or at risk of developing diseases involving aberrant TDP-43 expression such as FTD, ALS and/or AD, optionally, because of genetic factors or subjects exhibiting early signs of developing such neurodegenerative diseases.
Resumen de: WO2026064802A1
Described herein is a gene therapy platform to restore GABAergic inhibition and improve cognition in neurodevelopmental disorders, epilepsies, sensory disorders, aging, and Alzheimer's disease, by increasing expression of the transcription factor Meis2 in parvalbumin-expressing inhibitory neurons (PV INs).
Resumen de: WO2026064194A1
Provided are methods for administering allogeneic induced pluripotent stem cells (iPSC)-derived midbrain dopaminergic progenitors to a subject for treatment of Parkinson's disease (PD). The midbrain dopaminergic progenitor cells are administered to 5 trajectories, each with 8 depositional sites, per putamen. Patients are operated on using a trans-frontal approach with an entry point near the coronal suture. Also provided are compositions and articles of manufacture for use in the methods.
Resumen de: WO2026064441A1
The disclosure is related to methods of treating a subject with Alzheimer's Disease (AD) using anti-amyloid beta (Aβ) therapy. The patient may be treated based on the measurement and analysis of biomarker levels, such as plasma Aβ42/40 ratio, pTau181 and pTau217. The disclosure includes a systematic approach called CP Convert for converting biomarker measurements across different analytical platforms, enabling comparison of pTau217 data from LC-MS/MS, SIMOA, and chemiluminescent enzyme immunoassay platforms. Methods demonstrate that pTau217 has superior diagnostic accuracy compared to Aβ42/40 ratio and pTau181 for detecting brain amyloid positivity. Implementation of pTau217 prescreening can significantly reduce Aβ-PET testing, decreasing patient burden and clinical trial costs. The CP Convert methodology can be validated using independent cohorts, demonstrating robust cross-platform conversion for research applications.
Resumen de: WO2026064401A1
The disclosure provides methods of treating neurodegenerative conditions, for example, amyotrophic lateral sclerosis, using a regimen of a chlorite salt, for example, sodium chlorite. The long-term survival of subjects receiving sodium chlorite and placebo are compared.
Resumen de: US20260083826A1
The present invention aims to provide a novel agent for treating Alzheimer's disease, a method for treating Alzheimer's disease, a method for screening for a candidate substance for a therapeutic drug for Alzheimer's disease, and the like. The present invention is a prophylactic and/or therapeutic agent for Alzheimer's disease comprising a peptide corresponding to dynamin 1. The peptide preferably corresponds to dynamin 1-pleckstrin-homology domain or dynamin 1-proline rich domain. In addition, the peptide is preferably encapsulated in nano-particles or linked to a peptide sequence that improve delivery of the peptide into the brain.
Resumen de: US20260085036A1
The present invention relates to compounds according to formula (I), which are prodrugs of the psychoactive compound phenethylamine or its derivatives. The prodrugs provided herein exhibit improved pharmacokinetic properties during uptake as compared to phenethylamine (or the respective phenethylamine derivative), as well as reduced side effects resulting from the metabolites thus formed. Due to the affinity of the active phenethylamine compound, inter alia, for the 5-HT2a-receptor, these prodrugs are particularly advantageous for use in therapy, e.g., in the treatment of depression, posttraumatic stress disorder (PTSD), Alzheimer's disease or dementia.
Resumen de: US20260083740A1
The present disclosure relates to methods for treating a patient diagnosed with Parkinson's Disease (PD) by administering an escalating dose of tavapadon and monitoring efficacy of PD treatment.
Resumen de: US20260083723A1
A therapeutic or preventive agent for amyotrophic lateral sclerosis has inhibitory action against ferroptosis. The therapeutic or preventive agent for amyotrophic lateral sclerosis contains a tetrahydroquinoline derivative or a pharmaceutically acceptable salt thereof as an active ingredient. Compositions for and methods of treating amyotrophic lateral sclerosis and inhibiting ferroptosis are also disclosed.
Resumen de: US20260085066A1
The present disclosure relates to bifunctional compounds that cause the degradation of LRRK2; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with LRRK2, including Parkinson's Disease.
Resumen de: AU2023463541A1
The present invention relates to use of a novel compound for preventing, alleviating or treating Alzheimer's disease, and the novel compound exhibits an inhibitory effect on tau protein aggregation. In addition, it was identified that presenilin 1 was reduced by treatment using the novel compound. Therefore, the novel compound can be effectively used in the development of a therapeutic agent for Alzheimer's disease.
Resumen de: WO2026064542A1
The present disclosure describes crystalline forms of 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salts and pharmaceutical compositions of same. Also described are methods of using the crystalline forms treating Alzheimer's Disease, Dementia with Lewy Bodies and Dry age-related macular degeneration in a subject in need thereof, comprising administering the crystalline form to the subject. Methods of making the solid forms are also described.
Resumen de: WO2026062257A1
New gelatinase inhibitors, processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy and/or prophylaxis of conditions wherein inhibition of gelatinases is useful such as epilepsy, schizophrenia, Alzheimer disease, autism (in particular associated to fragile X syndrome), mental retardation, mood disorders such as bipolar disorders, depression, vascular diseases such as ischemic stroke and atherosclerosis, inflammatory diseases such as multiple sclerosis and rheumatoid arthritis, drug addiction, neuropathic pain, lung diseases such as asthma and chronic obstructive pulmonary disease, cancer and sepsis.
Resumen de: EP4714940A1
New gelatinase inhibitors, processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy and/or prophylaxis of conditions wherein inhibition of gelatinases is useful such as epilepsy, schizophrenia, Alzheimer disease, autism (in particular associated to fragile X syndrome), mental retardation, mood disorders such as bipolar disorders, depression, vascular diseases such as ischemic stroke and atherosclerosis, inflammatory diseases such as multiple sclerosis and rheumatoid arthritis, drug addiction, neuropathic pain, lung diseases such as asthma and chronic obstructive pulmonary disease, cancer and sepsis.
Nº publicación: EP4712958A2 25/03/2026
Solicitante:
VANDRIA SA [CH]
Vandria SA
Resumen de: MX2025013613A
Disclosed are methods of treating amyotrophic lateral sclerosis (ALS). Also disclosed are methods of treating C9orf72 amyotrophic lateral sclerosis (C9-ALS).
BOPI
Sede Electrónica
